CN111635451A - Process for refining tanshinone IIA by multistage countercurrent extraction method - Google Patents
Process for refining tanshinone IIA by multistage countercurrent extraction method Download PDFInfo
- Publication number
- CN111635451A CN111635451A CN202010515755.0A CN202010515755A CN111635451A CN 111635451 A CN111635451 A CN 111635451A CN 202010515755 A CN202010515755 A CN 202010515755A CN 111635451 A CN111635451 A CN 111635451A
- Authority
- CN
- China
- Prior art keywords
- phase
- tanshinone iia
- countercurrent extraction
- multistage countercurrent
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 238000000605 extraction Methods 0.000 title claims abstract description 39
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 title claims abstract description 36
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000007670 refining Methods 0.000 title claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 15
- 230000018199 S phase Effects 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 9
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- 235000005412 red sage Nutrition 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000008399 tap water Substances 0.000 claims 1
- 235000020679 tap water Nutrition 0.000 claims 1
- 238000005265 energy consumption Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 8
- 244000132619 red sage Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
Abstract
The invention discloses a process for refining tanshinone IIA by a multistage countercurrent extraction method. The preparation method comprises the following steps: suspending the red sage root coarse powder in an aqueous solution (phase B) to a certain concentration, placing the red sage root coarse powder in a multistage countercurrent extraction tank, taking an organic solvent as an extraction phase (phase S), adjusting the flow rate of the phase S and the phase B, extracting tanshinone IIA in the red sage root by using a multistage countercurrent extraction mode, recovering an S phase solvent to obtain red solid, namely the tanshinone IIA coarse powder. The invention adopts a multi-stage countercurrent extraction process, ensures that all materials are fully contacted with the solvent, keeps larger concentration difference, accelerates the extraction rate and saves the dosage of the solvent. In addition, the operation temperature is room temperature, so that the thermal instability components are not decomposed, the energy consumption is saved, the extraction cost is reduced, and the extraction efficiency of the tanshinone IIA is improved.
Description
Technical Field
The invention belongs to the technical field of natural extract extraction and the field of medicines, and particularly relates to a process for refining tanshinone IIA by using a multistage countercurrent extraction method, which is applied to the field of medical health.
Background
Salvia miltiorrhiza is the dried root and rhizome of Salvia miltiorrhiza belonging to Labiatae, and is the most common Chinese medicine for promoting blood circulation and removing blood stasis in clinic. Salvia miltiorrhiza also has the effects of stimulating menstrual flow, relieving pain, clearing away heart-fire, relieving restlessness, cooling blood and resolving carbuncle. The salvia miltiorrhiza is applied to Chinese patent medicine preparations for treating cardiovascular diseases, such as tablets, capsules, granules and injection, has the functions of expanding blood vessels, reducing blood pressure and resisting thrombus, and has obvious curative effects on treating coronary heart disease, angina and tachycardia. Wherein tanshinone IIA is dissolved in organic solvent such as ethanol, acetone, diethyl ether, benzene, etc., and is slightly soluble in water. The extraction of tanshinone IIA has attracted great attention, and although a large number of literature reports exist on the extraction of tanshinone IIA, how to greatly improve the purity of tanshinone IIA is not high, which is the direction of development and research of related technicians.
In clinical practice, the traditional Chinese medicine salvia miltiorrhiza has been widely applied to the treatment of cardiovascular and cerebrovascular diseases and stroke diseases. Tanshinone IIA has potential therapeutic effect on cardiovascular disease, cerebrovascular disease, tumor, leukemia, etc.
Aiming at the low content of tanshinone IIA extracted from Salvia miltiorrhiza, the invention provides a process for refining tanshinone IIA by using a multi-stage countercurrent extraction method.
Disclosure of Invention
Aiming at the low content of tanshinone IIA extracted from Salvia miltiorrhiza, the invention provides a process for refining tanshinone IIA by using a multi-stage countercurrent extraction method.
The invention is realized by adopting the following technical scheme:
a process for refining tanshinone IIA by using a multistage countercurrent extraction method comprises the following steps: suspending Saviae Miltiorrhizae radix coarse powder in aqueous solution (phase B), placing into a multistage countercurrent extraction tank, taking organic solvent as extractant (phase S), adjusting flow rate of phase S and phase B, extracting and purifying tanshinone IIA in Saviae Miltiorrhizae radix by multistage countercurrent extraction, recovering solvent of phase S, and obtaining red solid.
In order to detect the content of tanshinone IIA in the tanshinone IIA extract, the content and purity of the extract are measured by the method, and the measuring method comprises the following steps:
chromatographic conditions and system applicability test, the chromatographic column is ODSC18 column; water-acetonitrile (20: 80) is used as a mobile phase; the detection wavelength is 272 nm; flow rate: 1.0 mL/min.
Preparation of a reference stock solution: accurately weighing 10.0 mg of tanshinone IIA reference substance dried under reduced pressure for 24 h, placing in a 10 mL brown volumetric flask, adding mobile phase for dissolving, fixing volume to scale, and shaking to obtain tanshinone IIA reference substance stock solution.
And (3) sample determination: precisely sucking 20 μ L of sample solution, injecting into high performance liquid chromatograph, and measuring by the method.
The invention has the following advantages:
the invention adopts the countercurrent extraction process, maintains larger concentration difference, increases the extraction driving force, accelerates the extraction rate, saves the solvent consumption, has low extraction temperature, ensures that the thermal unstable components are not decomposed by low-temperature extraction, saves energy consumption, greatly reduces the extraction cost, improves the concentration of the effective components in the final solvent, and improves the extraction efficiency of the tanshinone IIA. The organic solvent is adopted for extraction, so that the workload of subsequent separation and concentration procedures is reduced, the production period of products is shortened, the labor production efficiency is greatly improved, and the energy consumption is reduced.
Compared with the prior art, the method for purifying the tanshinone IIA extract disclosed by the invention is different from the method for purifying the tanshinone IIA extract by adopting resin purification or preparative chromatography and the like reported in general literatures, has the advantages of simplicity and effectiveness in operation, easiness in industrialization and the like, and can effectively avoid the use of organic reagents which are toxic and harmful to human bodies. The purified tanshinone II A extract is more beneficial to exerting the pharmacological activity and eliminating the side effect of ineffective impurities.
The invention adopts low-cost organic solvent as the purification reagent, improves the content of tanshinone IIA higher than other reagents, and greatly reduces the process cost.
Detailed Description
The following examples are intended to further illustrate the invention, but are not intended to limit the invention.
Example 1
A process for refining tanshinone IIA by using a multistage countercurrent extraction method comprises the following steps: taking 20 mg/ml of salvia miltiorrhiza coarse powder aqueous solution in a primary countercurrent extractor, wherein the flow rate of S phase is as follows: phase B flow rate =1: 1. Recovering solvent from S phase, drying to obtain red solid, and measuring tanshinone II A content in coarse powder to be 1.60% and refined tanshinone II A purity to be 19.44% by high performance liquid chromatography.
Example 2
A process for refining tanshinone IIA by using a multistage countercurrent extraction method comprises the following steps: suspending l radix Salviae Miltiorrhizae coarse powder in 1% sodium bicarbonate water solution, wherein the concentration of radix Salviae Miltiorrhizae coarse powder is 30 mg/ml, placing in a two-stage countercurrent extractor, selecting ethyl acetate as S phase, and the flow rate of S phase is as follows: b phase flow rate =1: 5. Recovering solvent from S phase, drying to obtain red solid, determining tanshinone II A content in coarse powder to be 1.60% by high performance liquid chromatography, and refined tanshinone II A purity to be 31.00%.
Example 3
A process for refining tanshinone IIA by using a multistage countercurrent extraction method comprises the following steps: suspending l red sage root coarse powder in 5% sodium bicarbonate water solution, wherein the concentration of the red sage root coarse powder is 50 mg/ml, placing the red sage root coarse powder in a three-stage countercurrent extractor, selecting ethyl acetate as an S phase, and the flow rate of the S phase is as follows: b phase flow rate =3: 2. Recovering solvent from S phase, drying to obtain red solid, determining tanshinone II A content in coarse powder to be 1.60% by high performance liquid chromatography, and refined tanshinone II A purity to be 59.06%.
Claims (6)
1. A process for refining tanshinone IIA by a multistage countercurrent extraction method is characterized by comprising the following steps: suspending Saviae Miltiorrhizae radix coarse powder in water solution (B phase) to a certain concentration, placing in a countercurrent extraction tank, adjusting flow rate of S phase and B phase with organic solvent as extractant (S phase), extracting tanshinone IIA in Saviae Miltiorrhizae radix by multistage countercurrent extraction process, volatilizing solvent, and drying to obtain red solid.
2. The process for refining tanshinone IIA by multistage countercurrent extraction as claimed in claim 1, wherein: the concentration of the red sage root coarse powder is 5-100 mg/mL.
3. The process for refining tanshinone IIA by multistage countercurrent extraction as claimed in claim 1, wherein: the S phase is organic solvent immiscible with water, such as ethyl acetate, chloroform, dichloromethane, n-butanol, etc., preferably ethyl acetate.
4. The process for refining tanshinone IIA by multistage countercurrent extraction as claimed in claim 1, wherein: the phase B solvent is water or alkaline aqueous solution, such as tap water, purified water, sodium bicarbonate aqueous solution, sodium carbonate aqueous solution, sodium hydroxide aqueous solution, lime aqueous solution, etc., preferably alkaline aqueous solution.
5. The process for refining tanshinone IIA by multistage countercurrent extraction as claimed in claim 1, wherein: the phase ratio is S phase (extractant): phase B (crude solvent) =1:5-5: 1.
6. The process for refining tanshinone IIA by multistage countercurrent extraction as claimed in claim 1, wherein: the countercurrent extraction mode is multistage, and the stage number can be single stage, two stages, three stages, four seasons, five stages and the like.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010515755.0A CN111635451A (en) | 2020-06-09 | 2020-06-09 | Process for refining tanshinone IIA by multistage countercurrent extraction method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010515755.0A CN111635451A (en) | 2020-06-09 | 2020-06-09 | Process for refining tanshinone IIA by multistage countercurrent extraction method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111635451A true CN111635451A (en) | 2020-09-08 |
Family
ID=72329931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010515755.0A Pending CN111635451A (en) | 2020-06-09 | 2020-06-09 | Process for refining tanshinone IIA by multistage countercurrent extraction method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111635451A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101073599A (en) * | 2007-06-18 | 2007-11-21 | 石任兵 | Total tanshinone and total phenolic acid extract in red-rooted salvia root and its production |
| CN103479723A (en) * | 2013-08-21 | 2014-01-01 | 浙江中医药大学 | Diterpenoid tanshinone effective part and countercurrent chromatography preparation method and cancer treatment application thereof |
| CN103665094A (en) * | 2013-10-22 | 2014-03-26 | 南京慧博生物科技有限公司 | Preparation method for extracting and purifying tanshinone monomeric compounds from red sage root |
| CN109248467A (en) * | 2018-10-30 | 2019-01-22 | 安阳晶森生物科技有限公司 | A kind of technique extracting total-tanshinone from Radix Salviae Miltiorrhizae |
| CN110063981A (en) * | 2019-05-14 | 2019-07-30 | 西南医科大学 | A kind of technique and its application preparing total-tanshinone from Radix Salviae Miltiorrhizae |
-
2020
- 2020-06-09 CN CN202010515755.0A patent/CN111635451A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101073599A (en) * | 2007-06-18 | 2007-11-21 | 石任兵 | Total tanshinone and total phenolic acid extract in red-rooted salvia root and its production |
| CN103479723A (en) * | 2013-08-21 | 2014-01-01 | 浙江中医药大学 | Diterpenoid tanshinone effective part and countercurrent chromatography preparation method and cancer treatment application thereof |
| CN103665094A (en) * | 2013-10-22 | 2014-03-26 | 南京慧博生物科技有限公司 | Preparation method for extracting and purifying tanshinone monomeric compounds from red sage root |
| CN109248467A (en) * | 2018-10-30 | 2019-01-22 | 安阳晶森生物科技有限公司 | A kind of technique extracting total-tanshinone from Radix Salviae Miltiorrhizae |
| CN110063981A (en) * | 2019-05-14 | 2019-07-30 | 西南医科大学 | A kind of technique and its application preparing total-tanshinone from Radix Salviae Miltiorrhizae |
Non-Patent Citations (2)
| Title |
|---|
| 杨志伟 等: "丹参中丹参酮ⅡA和隐丹参酮的提取纯化工艺", 《扬州大学学报(自然科学版)》 * |
| 苏会东等: "《水污染控制工程》", 31 May 2017, 中国建材工业出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101186572B (en) | Method for separating and purifying salvianolic acid from red sage root liquid extract by one step | |
| CN100420665C (en) | Method for extracting 'Danfen' phenolic acid-A | |
| CN101260131A (en) | Method for extracting iridoid active site and monomer from eucommia bark | |
| CN103160549A (en) | Method of preparing, separating and purifying baicalein and wogonin by endogenous enzymatic hydrolysis of baicalin and wogonoside in scutellaria | |
| CN104592341A (en) | Method for extracting asiaticoside and madecassoside from centella | |
| CN100439319C (en) | Method for preparing salviol acid A | |
| AU2020101569A4 (en) | A Method of Extracting Xanthotoxol from the Root of Angelica Dahurica | |
| CN103180334B (en) | Prepare the method for lactone glucoside of Radix Paeoniae and peoniflorin | |
| CN1436553A (en) | Method of extracting effective component in red sage | |
| CN101348474A (en) | Method for preparing salvianolic acid B and tanshinol from Salvia miltiorrhiza stem | |
| CN104910216A (en) | Separation method for obtaining a plurality of epimeddium flavones by preparative liquid chromatography | |
| CN109939106B (en) | Application of sesquiterpene compound separated from Vernonia anthelmintica in preparing medicine for treating vitiligo | |
| CN111635451A (en) | Process for refining tanshinone IIA by multistage countercurrent extraction method | |
| CN103450286A (en) | Separation and preparation method for four iridoid glycoside monomeric compounds in lamiophlomisrotata | |
| CN102432573A (en) | Method for preparing lovastatin | |
| CN103275237A (en) | Preparation method and application of eggplant branch polysaccharide | |
| CN115710294A (en) | Method for extracting astragalus flavone by treating high-viscosity eutectic solvent through circulating pulse ultrasonic | |
| CN113440547B (en) | Method for separating and purifying Japanese thistle herb total glycosides by adopting macroporous resin series dynamic axial compression column | |
| CN101863957B (en) | Method for synchronously extracting tanshinone IIA and salvianolic acid B from danshen root efficiently | |
| CN108409570A (en) | Acetylshikonin rapidly and efficiently purification process in Asian puccoon | |
| CN108794443A (en) | A method of preparing high-purity cyanidenon | |
| CN105646638B (en) | The preparation method of pedunculoside | |
| CN105294789A (en) | Preparation method of high-purity salidroside | |
| CN103113196B (en) | Glechoma longituba phenol, and preparation method and application thereof | |
| CN111675741A (en) | Separation method for simultaneously obtaining four kinds of epimedium rare flavone by using preparative liquid phase method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200908 |
|
| RJ01 | Rejection of invention patent application after publication |